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Background. Human immunodeficiency virus (HIV) treatment guidelines have evolved, shifting from more-
aggressive to more-conservative approaches. The potential impact of these shifts on the transmission of drug-
resistant virus is unknown.
Methods. Drug-resistance genotypes were examined in all consecutive patients with recent HIV type 1 (HIV-
1) seroconversion (hereafter, “HIV-1 seroconverters”) seen at 10 Spanish hospitals since 1997. During the same
period, the proportion of patients with chronic HIV-1 infection having undetectable viremia was examined, to
estimate the extent and effectiveness of antiretroviral therapy.
Results. A total of 141 recent HIV-1 seroconverters were identified, 67.4% of whom were men who have sex
with men. The rate of primary drug-resistance mutations, by year of infection, was 33.3% for 1997, 29.4% for
1998, 20% for 1999, 14.3% for 2000, 3.4% for 2001, 15.4% for 2002, and 10.9% for 2003. On the other hand,
the proportion of 8388 persons with chronic HIV-1 carriage who had an undetectable virus load was 33.4% for
1997, 34.6% for 1998, 39.7% for 1999, 47.5% for 2000, 52.9% for 2001, 39.7% for 2002, and 58.1% for 2003. A
significant inverse correlation between transmission of drug-resistant HIV-1 and undetectable virus load was found
( , by Spearman’s test; ). The lowest rate of transmission of drug-resistant HIV-1 was seen inrp0.955 Pp .001
2001, when relatively “aggressive” treatment guidelines were used. Transmission of drug-resistant HIV-1 increased
in 2002, in parallel with a reduction in the number of patients with chronic HIV-1 carriage and undetectable virus
load, reflecting the popularity of drug holidays or treatment interruptions.
Conclusion. The rate of drug resistance in recent HIV-1 seroconverters inversely correlates with the proportion
of chronically HIV-1–infected individuals who have undetectable virus loads in the same region, which indirectly
reflects antiretroviral treatment rules at any given time.
Resistance to antiretroviral drugs represents one of the
major obstacles for the success of HIV-1 therapy [1].
Viruses that carry drug-resistance mutations can be
transmitted to and subsequently compromise the re-
sponse to antiretroviral therapy in drug-naive individ-
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uals [2–4]. In Western countries, where many HIV-1–
infected subjects are receiving antiretroviral therapy, an
increase in the prevalence of primary drug resistance
among patients with new HIV-1 seroconversion (here-
after, “HIV-1 seroconverters”) has been noticed in re-
cent years [4–6]. Accordingly, updated guidelines rec-
ommend drug resistance testing before antiretroviral
treatment is initiated for subjects with recently acquired
HIV-1 infection [7, 8].
In Spain, surveillance studies conducted during the
1990s have demonstrated that the rate of genotypic
resistance among drug-naive individuals with chronic
HIV-1 infection decreased significantly from 1997 to
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2000 [9–11]. However, data from HIV-1 seroconverters are
scarce, although alarming rates of primary drug resistance were
reported in the late 1990s [12, 13]. In parallel, HIV-1 treatment
guidelines have evolved over the past few years, shifting from
more-aggressive to more-conservative approaches [14, 15].
We were interested to know the extent to which changes in
antiretroviral treatment recommendations may have influenced
trends in the proportion of drug-resistant viruses in newly in-
fected individuals. For this purpose, and given the strong cor-
relation found between plasma HIV-1 RNA level and infec-
tiousness [16], we assumed that the proportion of patients with
chronic HIV-1 infection who have detectable plasma virus loads
indirectly reflects the population of potential transmitters.
Thereafter, we confronted it with yearly rates of primary drug
resistance among recent HIV-1 seroconverters. Specimens and
information from a relatively large number of newly infected
persons identified in different Spanish cities were assessed.
PATIENTS AND METHODS
Study Population
Recent HIV-1 seroconverters. All consecutive individuals with
new HIV-1 infection seen during the period of January 1997
through December 2003 at 10 different hospitals distributed
across Spain (A Corun˜a, Co´rdoba, Granada, Madrid [2 hos-
pitals], Ma´laga, Oviedo, Santander, Valencia, and Valladolid)
were examined. The eligibility criteria for a given subject to be
enrolled in the study were laboratory evidence of acute primary
HIV-1 infection (detectable plasma HIV-1 RNA level plus neg-
ative or indeterminate HIV-1 antibody test result) or seropos-
itivity for HIV-1 infection (reactive ELISA and Western blot
results) and negative results of a previous test performed within
the prior 12 months.
Chronic HIV-1 carriers. During the same 7-year period,
the proportion of patients with demonstrable HIV-1 infection
that had lasted at least 3 years and with undetectable virus loads
(!500 or !50 HIV-1 RNA copies/mL) was examined in a total
of 8388 individuals. Considering that patients with chronic
HIV-1 infection are regularly seen every 3 months in the out-
patient clinic, only consecutive samples collected during the
first trimester of each year were analyzed. The population in-
cluded subjects who were drug naive and those who were re-
ceiving antiretroviral therapy. We assumed that most patients
with undetectable virus loads were receiving successful anti-
retroviral therapy, reflecting indirectly the extent of therapy in
this population.
Laboratory Tests
The measurement of plasma HIV-1 RNA level was performed
using a branched DNA assay (Versant, versions 2.0 and 3.0;
Bayer), in accordance with the manufacturer’s instructions. The
lower limits of detection of the assay were 500 HIV-1 RNA copies/
mL during 1997 and 1998 and 50 HIV-1 RNA copies/mL since
1999. The CD4+ T lymphocyte count was determined by flow
cytometry (Coulter) using fluorescein-labelled antibodies.
Genetic sequence analyses of both HIV-1 reverse-transcrip-
tase (RT) and protease genes were performed for all plasma
specimens obtained from recent HIV-1 seroconverters using an
automatic sequencer (ABI Prism 3100; Celera Diagnostics). For
the purpose of this study, only major or primary drug-resistance
mutations listed in the latest guidelines from the International
AIDS Society–USA panel were recorded (http://www.iasusa.org;
updated November 2004). HIV-1 subtyping was performed us-
ing pol sequences by phylogenetic analyses, as previously de-
scribed [17].
Statistical Analyses
Baseline characteristics of the study population were recorded
as percentages or as mean . The proportion ofvalues SDs
patients with drug-resistance mutations and undetectable virus
loads was also recorded as a percentage. Nonparametric tests
were used to compare the proportion of patients with drug-
resistance mutations at different time points. Spearman’s test
was used to analyse the correlation between the rate of drug-
resistance mutations in recent HIV-1 seroconverters and the
proportion of potential transmitters at different time points.
All reported P values were 2-sided and were considered as
significant if less than .05.
RESULTS
A total of 141 recent HIV-1 seroconverters were identified. The
median estimated time from initial exposure to the first de-
tection of HIV-1 infection was 7.6 months. Overall, 67.4% had
been infected through homosexual sex. The prevalence of ge-
notypes associated with drug resistance in this population was
14.2% (20 of 141 genotypes).
The distribution of resistance genotypes is summarized in
table 1. Primary mutations at the RT gene were T215Y (4
subjects), M41L (4), M184V (2), Y181C (2), K103N (2), L210W
(2), D67N (1), T69N (1), and K219Q (1). Moreover, 7 subjects
presented with revertant forms at position 215 (C/D/L/N/S).
At the protease gene, primary resistance mutations were L90M
(3 subjects), M46L (2), and V82A (2). Five subjects had resis-
tance mutations to 11 drug family. Two of these subjects pre-
sented with mutations associated with resistance to nucleoside
RT inhibitors and nonnucleoside RT inhibitors, and another 3
presented with mutations associated with resistance to nucle-
oside RT inhibitors and protease inhibitors.
The overall proportions of primary drug-resistance muta-
tions, by year of infection, were 33.3% for 1997, 29.4% for
1998, 20% for 1999, 14.3% for 2000, 3.4% for 2001, 15.4% for
2002, and 10.4% for 2003. When we used different periods of
time, the proportions were 29% for 1997–1999, 5.6% for 2000–
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Table 1. Characteristics of patients with recent HIV-1 seroconversion who harbor drug-resistant virus.
Patient
Year of
seroconversion
Estimated
duration of
HIV infection,
months Risk group
Plasma HIV
RNA level,
copies/mL
CD4
cell count,
cells/mL
Drug-resistance mutations
RT Protease
1 1997 12 MSM 2880 472 T215L, K219Q …
2 1997 11 MSM 1925 717 T215Y …
3 1997 6 Heterosexual 500 Unknown M41L …
4 1998 12 Heterosexual 8876 545 M41L, L210W, T215D …
5 1998 12 MSM Unknown Unknown M41L, D67N, L210W,
T215Y, Y181C
…
6 1998 12 Heterosexual 13,070 678 M184V M46L, L90M
7 1998 7 MSM 39,420 689 T215Y …
8 1998 12 IDU 9330 1302 M41L …
9 1999 4 Heterosexual 20,401 840 T215N …
10 2000 9 MSM 500,000 530 … M46L
11 2001 11 MSM Unknown Unknown M41L, T215 …
12 2002 12 MSM 187,459 736 M41L, T215C …
13 2002 11 MSM Unknown Unknown M41L, T215S V82A, L90M
14 2002 6 MSM 2464 1023 Y181C …
15 2002 3 MSM 500,000 420 T69N …
16 2003 11 MSM 65,385 656 M41L, T215Y V82A, L90M
17 2003 3 Heterosexual 500,000 Unknown T215S …
18 2003 12 Heterosexual Unknown Unknown M184V, K103N …
19 2003 9 MSM 123,761 805 M41L …
20 2003 10 Heterosexual 75,000 257 K103N …
NOTE. IDU, injection drug user; MSM, men who have sex with men; RT, reverse transcriptase.
2001, and 12.5% for 2002–2003. There was a significant de-
crease between the first and second periods ( ), andPp .014
there was a rebound between the second and third periods,
although this did not achieve statistical significance ( )Pp .211
(figure 1). All but 2 patients were infected with HIV-1 subtype
B viruses. One of the remaining 2 subjects presented with sub-
type C virus in 2001, and the other presented with a BG re-
combinant (CRF14_BG) virus in 2003.
At total of 8388 patients with chronic HIV-1 infection seen
during 1997–2003 were examined. Only 1 plasma virus load
determination from each patient per year was evaluated. With
use of a detection limit of 500 HIV-1 RNA copies/mL, unde-
tectable virus loads were found for 44.6% of patients in 1997
and 48.6% in 1998; with use of a lower detection limit of 50
copies/mL, undetectable virus loads were noted for 37.5% of
patients in 1999, 47.5% in 2000, 52.9% in 2001, 39.7% in 2002,
and 58.1% in 2003.
To make the threshold for viremia uniform, we estimated
the virus loads for samples collected in 1997 and 1998 that
harbored !50 copies/mL instead of !500 copies/mL. In prior
studies [18–20], ∼75% of individuals with virus loads of !500
copies/mL in fact had virus loads of !50 copies/mL. With this
assumption, the proportions of patients with virus loads of !50
copies/mL in 1997 and 1998 were indirectly estimated to be
33.4% and 34.6%, respectively.
A significant inverse correlation between yearly rates of trans-
mission of drug-resistant viruses and the proportion of patients
with chronic HIV-1 carriage and undetectable virus loads was
found ( , by Spearman’s test; ). Figure 2rp0.955 Pp .001
shows the relationship between the proportion of individuals
with new HIV-1 infection who had drug-resistance mutations
and the effect of antiretroviral therapy on plasma virus load in
chronic carriers throughout the study period.
DISCUSSION
The widespread use of HAART has lead to a dramatic reduction
in the morbidity and mortality of HIV-1–infected individuals
[14]. A reduction in HIV-1 load—often to undetectable levels—
is usually seen in patients who are receiving HAART. Given
that virus load titers correlate with the transmission risk for
HIV-1, either from mother to child [21, 22] or to sex partners
[16], it should not be surprising to find lower infectiousness
for patients who are receiving HAART [23]. However, virolog-
ical failure may appear after exposure to suboptimal therapy
or as consequence of poor compliance with treatment, allowing
drug-resistant viruses to emerge [1]. If individuals who harbor
drug-resistant viruses continue to engage in high-risk practices,
transmission of drug-resistant strains may occur, as was noticed
soon after antiretroviral therapy was first introduced [24].
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Figure 1. Rate of drug-resistance mutations in patients who had recent HIV-1 seroconversion and the proportion of patients with chronic HIV
carriage who had undetectable virus loads, 1997–2003. For 1997 and 1998, the percentage of subjects with an HIV RNA level of !50 copies/mL was
estimated.
In our study, 114% of recent HIV-1 seroconverters harbored
drug-resistant viruses. Fluctuations over time were noticed,
with the highest rate of transmission of drug-resistant strains
occurring between 1997 and 1999, followed by a reduction in
2000–2001 and a rebound in 2002–2003. These results are in
agreement with trends reported in other western European
countries [25–27]. Recent decreases in the rate of transmission
of drug-resistant HIV-1 have correlated with increases in the
transmission of non-B subtypes in France, Switzerland, and
Italy [28–30]. However, this was not observed in our study (we
found only 2 subjects who had recently been infected with non-
B strains) and has not been documented in other studies from
Spain [31] in which subtype B continues to be, by far, the most
predominant transmitted HIV-1 variant.
Differences in the proportion of patients with chronic HIV-
1 infection for whom HAART failed could explain our findings
for recent HIV-1 seroconverters. We analyzed the proportion
of patients with chronic HIV-1 carriage who had undetectable
virus loads, which mostly reflects the success of HAART in the
overall population. By contrary, those with detectable virus
loads are the potential transmitters. This group includes either
patients who are antiretroviral naive or those for whom therapy
is not successful. The latter is a larger population and is more
likely to carry drug-resistant strains.
The proportion of HIV-1–infected individuals with unde-
tectable virus loads steadily increased from 1997 to 2001, re-
flecting more-widespread use of HAART and application of
relatively more-aggressive treatment recommendations [32, 33].
The rate of drug resistance among recent HIV-1 seroconverters
steadily decreased during that period, suggesting that a growing
proportion of new HIV-1 infections involved treatment-naive
subjects. In 2002, concerns of drug toxicity led to widespread
use of drug holidays, structured treatment interruptions, and
more-conservative treatment rules [14, 15, 34]. Together, this
has resulted in an increased proportion of patients with chronic
HIV-1 infection who have detectable virus loads. Individuals
with prior antiretroviral exposure could then become potential
transmitters of drug-resistant viruses [35, 36]. In accordance
with this hypothesis, we found a rebound in the proportion of
drug-resistant strains among recent HIV-1 seroconverters in
the year 2002.
In 2003, worries about the use of structured treatment in-
terruptions and/or drug holidays [37], as well as the availability
and extensive use of new potent drugs (lopinavir/ritonavir and
tenofovir) [38, 39], seemed to revert the situation. Currently
more patients with undetectable viremia are seen again among
chronic HIV-1 carriers, and lower drug resistance rates are
found among HIV-1 seroconverters.
Our study has several limitations. First, the number of HIV-
1 seroconverters varied significantly from year to year. This is
mainly because of the introduction of new assays for the di-
agnosis of HIV-1 infection in recent years [40] that have allowed
the simultaneous detection of HIV-1 antigen and antibodies,
and because of a more active search for HIV-1 seroconverters;
in conjunction, these factors resulted in a higher rate of iden-
tification of primary HIV-1 infections during recent years. Sec-
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ond, the proportion of patients with undetectable virus loads
was used as a surrogate marker for the effectiveness of HAART.
However, some long-term nonprogressors may also have un-
detectable virus loads without having received any antiretroviral
therapy [41]. In our population of chronic carriers, we iden-
tified only 20 individuals who might be considered to belong
to this category; therefore, their impact was negligible. Third,
the population of potential transmitters we examined was quite
heterogeneous. On one hand, it included patients with no prior
exposure to therapy, but it also included subjects for whom
antiretroviral therapy failed. Only the latter group might harbor
drug-resistant strains more frequently. On the other hand, dif-
ferent levels of detectable virus may account for differences of
transmission efficiency [42, 43], and this aspect was not assessed
in our study. With all of these limitations in mind, however,
we feel that our data support the hypothesis that the appropriate
use of HAART is associated with a lower rate of transmission
of drug-resistant viruses. In this context, although new HIV-1
infections may continue to occur, they are likely to derive from
subjects who are antiretroviral naive, who rarely transmit drug-
resistant strains.
In summary, higher proportions of virological suppression
in chronic HIV-1 carriers associated with the use of HAART
correlate with lower rates of transmission of drug-resistant vi-
ruses among individuals with new HIV-1 infection in a given
community. Antiretroviral therapy has benefits for people other
than those who are receiving treatment, as recently highlighted
by others [44], and this should be emphasized, particularly in
the light of recent increased sexual risk behaviors among high-
risk groups [45–47] that result from a misperception that HIV-
1 infection is no longer a deadly illness.
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